Metabolism of Iron and Erythropoiesis-stimulating agents (ESA) in chronic kidney disease (CKD)

Metabolism of Iron and Erythropoiesis-stimulating agents (ESA) in chronic kidney disease (CKD) - MIE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001121

Enrollment

Registered

2008-04-22

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD (non-dialysis, dialysis)

Interventions

Treatment with long-acting ESA

dose of ESA and iron were changed by Hb concentration (target 10-11 g/dl). Treatment with traditional ESA

dose of ESA and iron were changed by Hb concentration (target 10-11 g/dl).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Kidney disease, require medical care 2)Followed in the outpatient of our hospital and associated clinic 3)Expected survival time is more than 6 months 4)Aged 20 to 90 years 5)Fully informed consent was obtained

Exclusion criteria

Exclusion criteria: 1)Malignancy 2)Malnutrition 3)Active inflammatory or infectious disease 4)Uncontrollable diabetes mellitus 5)Abdominal ascites or pleural effusion 6)Pregnancy 7)Inappropriate for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
metabolism of iron, oxidative stress, and factors of atherogenesis	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Department of Internal Medicine, Division of Nephrology and Dialysis

jin@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026